硼替佐米与沙利度胺方案治疗多发性骨髓瘤的临床疗效及对肾功能的影响

目的硼替佐米与沙利度胺方案治疗多发性骨髓瘤的临床疗效及对肾功能的影响。方法收集2018年1月至2020年5月对雅安市人民医院血液科142例多发性骨髓瘤患者进行了回顾性研究。根据所使用药物的不同将患者分为硼替佐米组和沙利度胺组,比较沙利度胺组和硼替佐米组患者治疗前后凝血功能3项指标、骨髓相关3项指标和肾功能3项指标,比较沙利度胺组和硼替佐米组患者临床疗效和不良反应发生情况。结果治疗后比较,硼替佐米组患者的活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、纤维蛋白原(FIB)、血清M蛋白、骨髓浆细胞、血红蛋白、尿溶酶体酶(NAG)、β2-微球蛋白(MG)、胱抑素(Cys-C)指标含量均显著优于沙利度胺组患者(P<0.05);硼替佐米组患者的临床疗效显著优于沙利度胺组患者(Z=11.294,P=0.023),不良反应发生情况显著低于沙利度胺组患者(P<0.05)。结论相比于沙利度胺治疗,多发性骨髓瘤患者使用硼替佐米治疗的效果更佳,术后并发症发生概率相对较低。

Clinical efficacy of bortezomib vs thalidomide regimen in treatment of multiple myeloma and their impacts on renal function

Objective To investigate the clinical efficacy of bortezomib vs thalidomide regimen in treat-ment of multiple myeloma and their impacts on renal function.Methods A retrospective study was conducted on 142 patients with multiple myeloma treated in department of hematology,Ya′an people′s hospital,between January 2018 and May 2020.According to different medications,the patients were divided into the bortezomib group and thalidomide group.Findings of three-item blood coagulation function,three bone marrow-related indexes,and three-item renal function were compared before and after treatment between the thalidomide and bortezomib groups.The statistical differences in clinical efficacy and adverse reactions between the two groups were also examined.Results After treatment,the bortezomib group showed significantly favorable results in APTT,PT,FIB,serum M protein,bone marrow plasma cells,hemoglobin,urine NAG,β2-MG,and Cys-C compared with the thalidomide group(P<0.05).The clinical efficacy was significantly better in the bortezomib group than that in the thalidomide group(Z=11.294,P=0.023).The incidence of adverse reactions was significantly lower in the bortezomib group than that in the thalidomide group(P<0.05).Conclusion Compared with thalidomide,bortezomib as a treatment of multiple myeloma is more effective,and with lower incidence of postoperative complications.